Agenus’ (AGEN) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Agenus (NASDAQ:AGEN) in a research note released on Tuesday,Benzinga reports. HC Wainwright also issued estimates for Agenus’ Q1 2025 earnings at ($1.85) EPS, Q2 2025 earnings at ($1.26) EPS, Q3 2025 earnings at ($0.90) EPS, Q4 2025 earnings at ($0.61) EPS, FY2025 earnings at ($4.37) EPS, FY2026 earnings at ($3.79) EPS, FY2027 earnings at ($3.25) EPS, FY2028 earnings at ($3.48) EPS and FY2029 earnings at ($2.32) EPS.

Separately, Robert W. Baird lowered their target price on Agenus from $6.00 to $3.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 12th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat, Agenus currently has an average rating of “Hold” and an average target price of $8.75.

Agenus Stock Down 3.5 %

NASDAQ:AGEN opened at $1.67 on Tuesday. The stock’s 50 day moving average price is $3.04 and its 200 day moving average price is $3.70. The company has a market capitalization of $39.18 million, a PE ratio of -0.15 and a beta of 1.23. Agenus has a 52-week low of $1.64 and a 52-week high of $19.69.

Agenus (NASDAQ:AGEN) last released its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.36) by $0.32. The firm had revenue of $26.84 million for the quarter, compared to analysts’ expectations of $30.09 million. As a group, sell-side analysts anticipate that Agenus will post -12.55 EPS for the current fiscal year.

Institutional Trading of Agenus

A number of institutional investors have recently modified their holdings of the business. Barclays PLC boosted its stake in shares of Agenus by 17.7% in the fourth quarter. Barclays PLC now owns 32,737 shares of the biotechnology company’s stock valued at $90,000 after buying an additional 4,924 shares in the last quarter. HighTower Advisors LLC boosted its stake in shares of Agenus by 46.1% in the third quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 7,530 shares in the last quarter. State Street Corp boosted its stake in shares of Agenus by 2.1% in the third quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock valued at $2,563,000 after buying an additional 9,731 shares in the last quarter. EP Wealth Advisors LLC purchased a new stake in shares of Agenus in the third quarter valued at approximately $55,000. Finally, Point72 DIFC Ltd boosted its stake in shares of Agenus by 380.0% in the third quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 11,542 shares in the last quarter. 61.46% of the stock is currently owned by hedge funds and other institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.